Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana
This article was originally published in The Tan Sheet
Tennessee’s meth lab seizures are up this year, but CHPA says that’s because more labs are uncovered through the state’s participation in the NPLEx stop-sale system. Rx-only bills have stalled in several states, including Indiana, where lawmakers passed a bill to cap PSE purchases at about 61 grams per year.
You may also be interested in...
Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
Tennessee Emerges As PSE Battleground With Rx, NPLEx Proposals
The conflict between electronic tracking of pseudoephedrine purchases and shifting the drug ingredient to prescription-only status is elevated in Tennessee as lawmakers offer bills for both anti-methamphetamine strategies.
Mississippi PSE Prescription Switch Will Not Start An Avalanche - CHPA
Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts